Second Circuit Revives "Maximum Strength" Decongestant Claims Against Drug Manufacturers

Appellate Court Allows Key Consumer Fraud Claims to Move Forward

Consumers rely on over-the-counter medications to provide safe and effective relief from common illnesses. When manufacturers make marketing claims about their products, consumers have the right to expect those statements to be truthful. A recent decision from the U.S. Court of Appeals for the Second Circuit reinforces that principle by allowing important consumer protection claims involving "Maximum Strength" oral decongestants to proceed.

The litigation centers on oral phenylephrine (PE), an active ingredient found in numerous over-the-counter cold and flu medications. In recent years, scientific research and an FDA advisory committee concluded that oral phenylephrine is ineffective as a nasal decongestant. Despite these findings, consumers alleged that manufacturers continued to market products containing the ingredient using misleading advertising and labeling.

In its recent opinion, the Second Circuit affirmed that many state-law claims were preempted because manufacturers followed existing FDA labeling requirements. However, the court reached a different conclusion regarding products marketed as "Maximum Strength." Because those claims were voluntarily added by manufacturers rather than required by federal regulations, the court determined they may still be challenged under state consumer protection laws if they are alleged to be false or misleading. The court also revived certain claims involving products approved through the FDA's New Drug Application process.

The ruling represents an important development for consumers seeking accountability when companies choose to make marketing claims that extend beyond federally required labeling. It also demonstrates that manufacturers may still face legal scrutiny for promotional language that could influence purchasing decisions.

At Sultzer & Lipari, PLLC, protecting consumers from deceptive business practices remains a core focus of the firm's practice. Class action litigation serves an important role in holding corporations accountable when misleading advertising, defective products, or unfair business practices impact large groups of consumers. Cases like this help reinforce the principle that companies should provide accurate and transparent information so consumers can make informed decisions about the products they purchase.

While the litigation is ongoing and no final determination has been made regarding liability, the Second Circuit's decision allows consumers to continue pursuing claims related to "Maximum Strength" marketing representations. As the case returns to the district court for further proceedings, it will continue to be closely watched for its potential impact on consumer protection law and pharmaceutical advertising nationwide.

If you believe you have been harmed by deceptive marketing, misleading product representations, or other unfair business practices, the experienced attorneys at Sultzer & Lipari, PLLC are committed to protecting consumers' rights and pursuing accountability on behalf of those affected.